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Abstract
Endometrial carcinoma (EC) is the fourth most common cancer in women in the developed world. Classification of
ECs by histomorphologic criteria has limited reproducibility and better tools are needed to distinguish these tumors
and enable a subtype-specific approach to research and clinical care. Based on the Cancer Genome Atlas, two
research teams have developed pragmatic molecular classifiers that identify four prognostically distinct molecular
subgroups. These methods can be applied to diagnostic specimens (e.g., endometrial biopsy) with the potential to
completely change the current risk stratification systems and enable earlier informed decision making. The
evolution of genomic classification in ECs is shared herein, as well as potential applications and discussion of the
essential research still needed in order to optimally integrate molecular classification in to current standard of care.
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Background
Cancer care in the last decade has featured a concerted
move towards the personalization of patient care, often
called precision medicine. In the field of cancer, this has
meant a progression from broad categorization of tumors
by anatomic site, to distinguishing subgroups by histomor-
phology, and more recently defining tumors by molecular
features. This evolution has not happened over night and
pace of change has varied by tumor site. Paradoxically,
despite endometrial cancer being the most common gyne-
cologic malignancy in women in Canada and the United
States [1, 2] and the 6th most common cancer in women
globally [3], research and clinical advancement have
arguably lagged as compared to other cancers. This
may be because over 75% of women diagnosed with
endometrial cancer have early stage disease (stage I or II)
and favorable outcomes (5-year overall survival 75–90%)
[4–6]. However, for those women who recur or for those
who present with more advanced disease, response rates
to conventional chemotherapy are low and clinical out-
comes are extremely poor [7–10].
Renewed research focus on this disease site has
been prompted by a dramatic increase in incidence
observed in the developed world [2, 11–13]. In
addition, there has been frustration with contemporary
practice, in part due to inconsistent EC histomorphologic
categorization, imprecise risk stratification, and diverse
treatment strategies. Multidisciplinary panel recommen-
dations on management of ECs [14] have emerged in an
effort to make treatment (surgery, chemotherapy, radio-
therapy, surveillance) more consistent. Multiple reviews
on state of the art care of EC’s have been published, and
increasingly the repercussions of treatment on patient
quality of life are being assessed in addition to survival
parameters [6, 15–20]. Attention to this balance of
treatment and sequelae may be even more essential in
this disease site as there is concern that many women
are likely over-treated or under-treated.
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There has been a call for the incorporation of molecu-
lar features in to both classification and risk determin-
ation of ECs in order to better assess the biological
behavior of an individual’s disease and ultimately to im-
prove treatment decisions and outcomes [21, 22]. The
objective of this review is to focus on the new genomic
framework used to categorize endometrial carcinomas.
Herein we describe the evolution of molecular classifica-
tion systems and how genomic characterization will im-




Thirty years ago, Bokhman hypothesized there were
two pathogenetic types of endometrial carcinomas
driven by very different metabolic and endocrine
signals [23]. Type 1 is more common (~70–80%), consist-
ing of endometrioid, low grade, diploid, hormone-receptor
positive tumors that are moderately- or well-differentiated
and more common in obese women. Patients presenting
with Type 1 tumors tend to have localized disease con-
fined to the uterus and a favourable prognosis. In contrast,
Type 2 tumors (20–30%) are more common in non-obese
women, of non-endometrioid histology, high-grade, aneu-
ploid, poorly differentiated, hormone receptor negative
and associated with higher risk of metastasis and poor
prognosis. While this historical system of taxonomy has
been useful, substantial heterogeneity within and overlap
between Type I and II cancers is now recognized. Type I
and Type II designation has never been part of the formal
staging nor risk stratification, and thus has no clinical
utility beyond providing a conceptual framework for
understanding endometrial cancer pathogenesis.
Endometrial classification by histomorphology
and current systems of risk stratification
Tumor grade and histologic subtype assessment are
subjectively assigned according to appearance under the
microscope and predefined pathologic criteria. Nuclear fea-
tures and the proportion of solid tumor vs. identifiable
glands defines grade 1–3. Histologic subtype is assigned by
morphologic criteria and often aided by immunostains.
Pathologic accuracy is hampered by poor diagnostic repro-
ducibility, especially in the case of high-grade subtypes (e.g.
grade 3 endometrioid, serous). Studies describe inter-ob-
server disagreement or lack of consensus on histologic
subtype diagnosis in one-third or higher of ECs [24–
27]. The overall kappa statistics for FIGO grade assign-
ment between pathologists is 0.41–0.68, indicative of
only moderate levels of inter-observer agreement [24,
28]. Agreement between diagnostic specimens and
final hysterectomy is also limited [29–32]. In short,
histologic classification is not accurate or precise
enough to effectively triage patients into optimal treat-
ment groups.
Endometrial carcinoma has been a surgically staged
disease since 1988. Surgery traditionally involves hyster-
ectomy with bilateral salpingo-oophorectomy +/− lymph
node dissection or sampling and omentectomy with several
safe options in surgical approach [14, 33–35]. Extent
of staging may vary according to patient age, comorbidi-
ties, cancer histology, grade, disease distribution, surgeon
preference and institutional practice. Surgery alone is typ-
ically sufficient to cure early-stage EC [14, 36, 37], how-
ever, it is recognized that tumors with ‘high-risk’ features
have a high likelihood of recurrence and adjuvant treat-
ment (radiation and/or chemotherapy) is recommended
[8, 16, 38, 39]. The major challenge is in distinguishing the
features that comprise ‘low-‘, ‘intermediate-‘, and ‘high-
risk’ disease in ECs. Multiple different risk predictive
clinical models have been developed to guide treatment
[14, 37, 40–48]. These have evolved with new FIGO
staging and through interpretation of large clinical
trials, however all incorporate the key pathological
parameters of histotype, grade, and stage. As mentioned
previously, the reproducibility of both histotype and
grade have been demonstrated to be poor in EC’s
[24, 26, 27], thus two of three major criteria for risk
group assignment which directly impacts recommenda-
tions for adjuvant treatment have limited reproducibil-
ity. Understandably, this makes it challenging to
confidently make treatment decisions. We know that
some women are undertreated who could have bene-
fited from aggressive surgery, chemotherapy and/or ra-
diation, and many may be overtreated having been
cured by surgery alone.
The adequacy of risk stratification systems in EC
have recently been compared and challenged [22, 49].
There are five major risk stratification systems in EC,
of which the modified European Society of Medical
Oncologists (ESMO) classification was demonstrated
to best discriminate for recurrence and nodal metasta-
ses in apparent early stage disease [49]. However, none
of the existing schemes were deemed highly accurate.
In addition, all current systems stratify women based
on pathologic data obtained after surgical staging
(stage is a component of risk assignment). There is
great need to obtain earlier and more biologically in-
formative data from EC tumors that could assist in
planning the optimal course of treatment for the indi-
vidual. In addition, diagnostic tools that could object-
ively and consistently categorize ECs into distinct
subgroups would enable stratification of clinical trials
and study of treatment efficacy within biologically ‘like’
subgroups. Stemming from clinical need and a recog-
nized inadequate/unsustainable system a call was made
for the integration of molecular features.
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A new genomic era: molecular classification of
endometrial carcinomas
Several research teams have defined immunohistochemical
and/or mutation profiles to aid in distinguishing EC sub-
types [50–58]. In one series, a set of seven immunohisto-
chemical markers was able to improve the distinction
between high-grade EC histotypes [28] and more recently,
another team demonstrated a nine protein panel improved
identification of both low and high-grade EC subtypes [57].
Sequencing has enabled further improvement, with a nine-
gene panel, demonstrating distinct mutational profiles for
the major EC histotypes [52]. Molecular data has also been
used to further stratify risk categories; using gene expres-
sion profiling and copy number analysis to determine risk
of recurrence [59, 60], even in apparent low stage disease
[61]. Molecular characterization has also been pursued for
potential therapeutic targets in EC, focusing on frequently
mutated pathways such as PI3K/PTEN/AKT/mTOR. Fur-
ther work is needed to define molecular biomarkers that
more accurately reflect tumor susceptibility [62–66].
The most comprehensive molecular study of ECs to
date has been The Cancer Genome Atlas (TCGA) project,
which included a combination of whole genome sequen-
cing, exome sequencing, microsatellite instability (MSI)
assays, and copy number analysis [67]. Molecular informa-
tion was used to classify 232 endometrioid and serous
endometrial cancers into four groups - POLE ultramu-
tated, MSI hypermutated, copy-number (CN) low, and
CN high - that correlate with progression-free survival.
The ultramutated POLE subgroup was a novel finding
from the TCGA, and generated interest due to its very
favorable outcomes even within high-grade tumors. In
TCGA, ultramutated cases were characterized by POLE
exonuclease domain mutations (EDM), a high percent of
C > A transversions, a low percent of C > G transver-
sions, as well as more than 500 SNVs. POLE encodes the
major catalytic and proofreading subunits of the Polε
(Polymerase Epsilon) DNA polymerase enzyme complex
responsible for leading strand DNA replication. The exo-
nuclease proofreading function and the high fidelity in-
corporation of bases by POLE ensures a low mutation
rate in the daughter strand. In ECs, POLE EDMs are
mostly found in hotspot regions with V411L and P286R
being the most common mutations. Substitutions in DNA
polymerases were shown to inactivate or suppress proof-
reading abilities, thus causing increased replicative error
rates and resulting in the ultra-mutated phenotype. In the
TCGA, whole genome or exome sequencing was used
to assess POLE status. Other series have subsequently
assessed POLE status using more focused methods includ-
ing Sanger sequencing [68, 69], gene panels [69–71], digital
PCR [72–74] or functional assays [75] and confirmed
very favourable outcomes for women with POLE aber-
rant ECs.
TCGA also described a molecular subgroup that ex-
hibited microsatellite instability (MSI). MSI arises from
defects in post-replicative DNA mismatch repair system.
In the TCGA, MSI was determined by a panel of four
mononucleotide repeat loci (polyadenine tracts BAT25,
BAT26, BAT40, and transforming growth factor receptor
type II) and three dinucleotide repeat loci (CA repeats in
D2S123, D5S346, & D17S250) in addition to the recom-
mended markers from the National Cancer Institute [76],
tumor DNA was classified as microsatellite- stable (MSS) if
zero markers were altered, low level MSI (MSI-L) if one to
two markers (less than 40%) were altered and high level
MSI (MSI-H) if three or more markers (greater than 40%)
were altered. Mismatch repair deficiencies can result
from i) an inherited cancer syndrome (e.g., Lynch), ii)
acquired/somatic mutations or iii) epigenetic events e.g.
methylation of one of the genes involved in mismatch
DNA repair, most commonly MLH1.
Finally TCGA distinguished a distinct molecular sub-
group by copy number analysis. Copy number was deter-
mined using Affymetrix SNP 6.0 microarrays using DNA
originating from frozen tissue. Hierarchical clustering
identified significantly reoccurring amplifications or
deletions regions and a ‘copy number (CN) high’ sub-
group. All remaining samples that did not belong to
the POLE ultramutated group, the MSI group, or the
CN high group, were termed CN low. The appeal of
objective molecular categorization of new EC cases in
to one of four prognostic subgroups was immediately
apparent. However, methodologies used for the TCGA
study were costly, complex and unsuitable for wider
clinical application.
Two research teams, including our own, have subse-
quently developed more pragmatic methodologies to
evaluate molecular features of ECs, working in standard
formalin-fixed paraffin-embedded tissue. These methods
do not identify molecular subgroups that are identical to
TCGA but do recapitulate the four survival curves ob-
served in TCGA [69, 71, 73, 77] (Fig. 1). Stelloo et al.
[69, 71] used a combination of TP53 mutational testing
and p53 IHC to determine p53 status obtained from se-
quencing as a surrogate for CN high TCGA subgroup.
The promega MSI analysis system was used to determine
MSI status. For tumors exhibiting low levels of instability
or from which extracted DNA quality was poor, immu-
nohistochemistry for mismatch repair (MMR) proteins
(MLH1, MSH2, MSH6, and PMS2) was performed. POLE
EDM hotspot mutations were identified by Sanger sequen-
cing. This team also tested for hotspot mutations (159)
across 13 genes (BRAF, CDKNA2, CTNNB1, FBXW7,
FGFR2, FGFR3, FOXL2, HRAS, KRAS, NRAS, PIK3CA,
PPP2R1A, and PTEN). Testing ultimately yielded four
molecular subgroups: group 1 - p53 (mutation identified),
group 2- MSI, group 3 –POLE (POLE EDM identified), and
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finally group 4 –NSMP, a group with ‘no specific molecular
profile’ (Fig. 1a). Tumors with insufficient tissue to perform
all molecular testing were not classified and tumors with
more than one molecular feature, constituting 2–3% of the
cohort, were also not classified. Due to this exclusion,
the order of mutational testing was irrelevant. This research
team initially assessed ECs from the PORTEC3 trial (n =
116), with known high risk features. Recurrence-free sur-
vival and time to distance metastasis were assessed within
the four molecular subgroups. They observed that patients
belonging to the POLE and the MSI subgroups showed
similar and much better survival outcomes in comparison
to the p53 mutant group and the NSMP group which ex-
hibited worse recurrence and distance metastasis outcomes
even within the endometrioid histology cases. Differences
in survival patterns relative to the TCGA results were at-
tributed to a greater proportion of high-risk features in the
PORTEC 3 cohort.
The Leiden/TransPORTEC group has since applied the
same series of molecular tests to a larger, more diverse co-
hort [71]. However, survival analysis and assessment of
prognostic ability was restricted to endometrioid subtype
and stage 1 tumors of patients with intermediate clinical
risk. Within this very specific group, the observed out-
comes associated with each molecular subgroup more
closely mirrored TCGA.
Our research team has also developed a molecular
classification system that uses practical methodologies to
assign ECs to one of four molecular subgroups with dis-
tinct survival outcomes. We have followed the Institute of
Medicine (IOM) guidelines for the development of ‘omics
based tests [78], initially exploring 16 models in a ‘discov-
ery’ cohort (n = 141) [73], next locking down sequence of
testing and methods to a single model termed ProMisE
(Proactive Molecular Risk Classifier for Endometrial
Cancer) on a new ‘confirmation’ cohort (n = 319) [77,
79] to prove feasibility and confirm the association
with outcomes/prognosis, and finally testing in a large ‘val-
idation’ cohort (n =~500) of ECs from collaborators at the
University of Tübingen (Germany). Molecular decision tree
analysis for ProMisE is outlined in Fig. 1b. Specific method-
ologies include immunohistochemistry (IHC) for the detec-
tion of the presence/absence of two mismatch repair
(MMR) proteins: MSH6 and PMS2. This identifies ‘MMR-
D’ (deficient) subgroup. Cases are then sequenced using
digital PCR to identify POLE exonuclease domain muta-
tions (‘POLE EDM’). Finally, cases are assessed using IHC
for p53 (wild type vs. null or missense mutations; ‘p53wt’
and ‘p53abn’, respectively). We have demonstrated that
women within each molecular subgroup have clinicopath-
ological characteristic that have consistently been shown
to be typical of that group. For example, the p53 abn sub-
group usually encompasses the highest proportion of high
grade, advanced stage, non-endometrioid histotypes and
arises in older, thinner women. Similarly, the emerging
phenotype of women whose EC harbor POLE EDMs is of
particular interest since it generally includes younger,
thinner and with surprisingly aggressive pathologic fea-
tures (large proportion of grade 3 tumors, many with deep
myometrial invasion and LVSI) yet consistently exhibit fa-
vorable outcomes. The MMR-D subgroup have very simi-
lar ‘uterine factors’ (clinicopathologic features in the
uterus itself) [48] to the POLE subgroup, i.e. a comparable
proportion of high grade tumors and deep myometrial in-
vasion and LVSI, yet they have worst observed outcomes
of any group next to p53abn [77, 79]. On multivariable
analysis, ProMisE molecular subgroup assignment main-
tained its association with overall survival (OS), progres-
sion free survival (PFS) and recurrence free survival (RFS)
even after correction of other clinicopathologic parameters
of known prognostic significance available at time of diag-
nosis/collection of diagnostic specimen for molecular ana-
lysis (e.g., age, BMI, grade, histotype but not stage).
Both ProMisE (across all tumors tested), and the Leiden
classifier (within the intermediate-risk group examined)
demonstrate comparable risk discriminatory ability to the
ESMO risk stratification system. Furthermore when clinical
and pathological features were integrated with molecular
features they resulted in improved risk stratification.
Through evaluation of the collective cohort (discovery +
Fig. 1 Schematic of the a Leiden/TransPORTEC and b ProMisE/
Vancouver molecular classification systems including testing performed,
molecular subgroups identified, and by what criteria cases would be
considered unclassifiable
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confirmation + validation cohorts = ~ 1000 ECs) we plan to
evaluate which key clinicopathological parameters can add
value to molecular classification giving high priority to
those features available at time of diagnosis (e.g., age, BMI).
Our goal has consistently been to develop a molecular
classification tool that could be applied to diagnostic
specimens (endometrial biopsy or curettage) and therefore
inform treatment at the earliest time point. Biologically
relevant information about an individual’s tumor could
guide surgical urgency and aggressiveness, fertility or
hormonal function sparing management options, adjuvant
therapy, and/or surveillance schedules. We have demon-
strated high concordance between ProMisE molecular clas-
sification in diagnostic vs. final hysterectomy samples, far
superseding concordance of grade, or histotype as assigned
on original pathology reports or within or between reviews
by expert gynecologic cancer pathologists [80]. The Leiden
team has also shown high concordance of molecular tumor
alterations between pre-operative curettage specimens
and final hysterectomy specimens (13 gene panel and
MSI assay) [81] and a multicenter, prospective trial in
Holland is in process to see if surgical management can
be improved [82]. As diagnostic specimens are fixed
immediately (in contrast to a hysterectomy specimen
that may sit for hours in an operating room before pro-
cessing in pathology), the quality of DNA extracted and
fixation for IHC is high. We believe one of the most ex-
citing aspects of molecular classification and what will
be most impactful in directing care for women with EC
will be this capability of determining earlier prognostic
(and possibly predictive) information.
Ultimately, integration of molecular classification by
either method into current practice, as performed on
diagnostic specimens or final hysterectomy, will need
to be studied in the context of a prospective clinical
trial; comparing survival outcomes, quality of life and
health economic implications to conventional/historical
standard of care.
Challenges with molecular classification: key
components
The Leiden/TransPORTEC and Vancouver/ProMisE prag-
matic molecular classification systems incorporate the same
integral components: identification of ECs with mismatch
repair deficiency/microsatellite instability, POLE exonuclease
domain mutations and aberrant p53. Similarities and
differences are shown in Fig. 1. Prognostic strength of
molecular classification is at least equivalent to other
clinicopathological features or risk stratification systems
but offers the advantage of objective results (e.g., presence
or absence of a protein or mutation). We believe these key
molecular components are unlikely to be outperformed by
any single clinicopathological parameter or biomarker. Not-
ably, as yet none of the additional immunohistochemical
markers we have tested across our endometrial cancer cases
have outperformed ProMisE. Although we and others are
investigating the immune landscape and specific immuno-
histochemical biomarkers within the context of these major
molecular subgroups these studies will not be covered in
this manuscript. Should any parameter improve the ability
to discern outcomes and guide management beyond
the ProMisE or Leiden molecular classification, they
can be incorporated into future algorithms. Herein, we
focus on some of the major challenges and consider-
ations for future implementation of molecular
classification.
MMR/MSI
There are different techniques for the identification of
mismatch repair deficiency [76, 83–87]. Both TCGA
and the Leiden series use microsatellite instability (MSI)
assays. These have primarily been utilized in research, not
clinical practice settings (there are no FDA-approved MSI
tests) and require DNA extraction from tumor as well as
normal tissue or blood for comparison. ProMisE tests for
the presence of two mismatch repair proteins (MSH6,
PMS2) by immunohistochemistry and we have shown high
concordance between MMR IHC and MSI assay methods
[83]. IHC staining for MMR and interpretation is routine
for most pathology laboratories. Unfortunately, although
histomorphologic surrogates for MMR deficiency or Lynch
syndrome have been explored (e.g., tumor infiltrating and/
or peritumoral lymphocytes, dedifferentiated histology,
lower uterine segment origin) [88, 89], as yet they have not
proven to be equivalent to molecular confirmation.
Although all MMR deficiencies are often grouped
together, for inherited mutations (Lynch syndrome),
the lifetime risk and age of penetration of Lynch-associated
cancers can vary substantially according which gene is aber-
rant [90]. This may impact recommendations regarding the
timing of screening or intervention e.g., lower lifetime risk
and later average age of penetration for individuals
with aberrant MSH6 [90–93] might enable delay of
recommended risk reducing surgery as compared to
other Lynch mutations.
Prognostic and predictive implications of mismatch re-
pair may also vary according to specific MMR gene muta-
tion or protein loss identified. It has been hypothesized that
epigenetic/methylation events in mismatch repair likely
have different implications on tumor characteristics and
clinical outcomes than germline defects e.g. an age-related
somatic event would not be expected to promote the devel-
opment of tumor that is equivalent to one arising in a
young individual harboring a germline mutation. Immune
environment, intrinsic biologic behavior, toleration of adju-
vant therapy/response to cell injury may vary significantly
in these individuals. This may partially explain the rela-
tively wide range of response to immunotherapy within
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MMR-D cases. At present, all mismatch repair deficien-
cies are lumped together but further interrogation of
these differences (e.g. subgroups of subgroups) is war-
ranted. Recently, over 1000 women with EC had their tu-
mors evaluated for microsatellite instability, MLH1
methylation, and MMR protein expression as part of a
combined NRG Oncology/Gynecologic Oncology Group
Study (GOG210) [94]. Categories of normal mismatch re-
pair, epigenetic defect and probable mutation (somatic or
germline) were compared to clinicopathologic variables
and clinical outcomes in the trial cohort. Even with this
large number of cases, these three broad categories of
MMR status were not shown to be associated with PFS or
DSS. Univariate analysis did suggest potentially worse PFS
for women whose tumors had epigenetic defects (trend, p
= 0.1) but this association was not maintained after
adjusting for other factors, including the highly relevant
parameter of age in this cohort. In addition, the authors
observed a trend to improved PFS in tumors with MMR
mutations and a suggestion that these patients received
greater benefit from adjuvant chemotherapy compared to
women with normal mismatch repair. Similar results for
probable germline/Lynch syndrome mismatch repair
deficient tumors were observed in a smaller series of
221 ECs, with no prognostic nor predictive associa-
tions noted in the tumors with methylation events
[95].
POLE
Several research teams have characterized POLE mutated
tumors by histomorphology and immune environment
[96–101]. Obvious clinical implications for tumors with
substantial immune infiltrates include selection for
anti-PD-1 therapy. However, the highly favorable out-
comes observed in women with POLE mutated tumors
would suggest that costly targeted therapy might better be
reserved for the very rare cases of recurrent or advanced
disease [102, 103]. POLE somatic mutations are found in
less than 10% of endometrial carcinomas and recurrence
is seldom observed; thus, it has been difficult for a single
study to be adequately powered to determine optimal
management of women whose tumors harbour this mo-
lecular feature. Adjuvant treatment is commonly adminis-
tered due to the frequency of ‘high-risk’ features in ECs
with POLE EDMs (e.g., relatively high frequency of grade
3, deep myometrial invasion, LVSI) but whether this is
over treatment of women who would do well based on
their POLE genotype alone or whether treatment is
needed and favorable outcomes are secondary to exquisite
sensitivity to DNA damaging agents in these tumors is as
yet unclear.
The paradox of observed aggressive histopathologic
features but excellent survival outcomes may in part be
explained by the high neoantigen load and immune rich
microenvironment in tumors with POLE EDMS (and to
a lesser degree, also described in MMR-D tumors).
Both sequencing and functional assays currently employed
for POLE mutation testing are more costly than IHC and
utilize methods that require a skilled team to perform and
interpret. We, and others, continue to search for surro-
gates for POLE sequencing. Although the clinical and
pathological phenotype of women with POLE mutated
tumors is beginning to be characterized; on average youn-
ger, lower BMI, high proportion of grade 3, LVSI+, pre-
dominantly endometrioid, and low stage, these parameters
overlap with other molecular subgroups. At present there
is no single pathognomonic surrogate for this feature.
p53
The mutational spectrum of TP53 mutations within ECs
was recently described in Schultheis et al. [104], both in
the context of histotype and across TCGA molecular
subgroups. This study confirmed the very high propor-
tion (91%) of TP53 mutations in the ‘CN high’ TCGA
category but also seen in 35% of the POLE genomic sub-
group. No clinical correlative data was provided with
their paper but our series and others confirm the highly
favorable outcome of POLE mutation carriers even with
the identification of other mutations traditionally associ-
ated with high risk disease. The order of our
categorization: identification and removal of POLE sub-
group prior to p53 stratification thus seems to be of
great importance (see tumors with >1 molecular feature
below). Also described in this series was the presence of
frameshift or nonsense TP53 mutations (22% of TP53
mutant subset) of which they acknowledge would yield
different IHC results (loss or IHC score 0) than missense
variants (IHC score 2). Identification of both aberrant
states is essential. Our team, in collaboration with others
is in the process of further characterizing both TP53 mu-
tational and IHC status in ECs in order to better guide
interpretation in this disease site.
Tumors with more than one molecular feature
Both Talhouk et al. [77, 79] and Stelloo [71] et al.
describe approximately 2-3% of endometrial tumors
having more than one of the key molecular features
described. Reported frequency of post-replication
POLE proofreading defect and a DNA mismatch re-
pair defects varies in the literature, but in series
where co-occurrence is higher, this has been attrib-
uted to somatic MMR mutations which may be sec-
ondary to the ultra-mutated POLE phenotype. [67,
70, 98]. Similarly, it is perhaps not surprising that in
both the POLE and MMR-D subgroups of ECs with
high mutational loads, tumors may also harbour
TP53 mutations (as evidenced by either sequencing,
or complete loss or overexpression of p53 protein on
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IHC) [71, 77, 79, 104]. The order of testing for mo-
lecular classification is therefore critically important.
Determination of POLE status prior to p53 testing
will categorize a given EC as POLE EDM. Favorable
outcomes are therefore anticipated for that individual,
and indeed for cases reported thus far with dual fea-
tures, that has been observed [77]. We believe testing
for MMR-D first is still valid, as that information is ar-
guably more actionable than POLE status (referral for
hereditary testing, consideration of immunotherapy)
which is not currently integrated into treatment algo-
rithms. Ultimately, distinguishing between what are likely
passenger mutations or late events without functional con-
sequence as compared to mutations that define biologic
behavior is essential. Molecular classification tools that
utilize large gene panels may detect a plethora of coexisting
mutations in POLE EDM ECs and need to be interpreted
with caution e.g., discovery of BRCA1 or BRCA2 mutation
in a POLE mutated EC may not indicate homologous re-
combination deficiency / PARPi efficacy [105].
Clinical outcomes may be harder to discern between
ECs demonstrating both MMR deficiency and p53 muta-
tions and the ‘best’ categorization of these tumors remains
to be determined. At present, molecular classification will
first identify the MMR deficiency at least enabling patients
to be referred for hereditary counselling and providing op-
portunities in genotype specific clinical trials.
Genotype-phenotype interplay
Genotype-phenotype interactions have been appreciated
and characterized in recent years. Although not the focus
of this review, we will take this opportunity to describe
one highly relevant example.
It is now appreciated that PTEN loss has different
prognostic implications in lean vs obese individuals.
Mutations in the central relay pathways of insulin signals
(phosphatidylinositol 3-kinase (PI3K) pathway including
mutations specifically in PIK3CA, PIK3R1 and PTEN) are
extremely common in ECs yet prior studies on the prog-
nostic significance of PTEN mutations had markedly dis-
cordant results. Westin et al. stratified cases by body mass
index (BMI) revealed improved progression free survival in
obese (BMI >30) women with endometrioid endometrial
carcinoma suggesting an interaction between metabolic
state and genetics [106]. Subsequently, a constellation of
‘obesity related’ genes are observed to be upregulated with
increasing BMI among endometrioid carcinomas in the
TCGA cohort [107], and different targets for treatment
were suggested in obese vs non-obese individuals [108].
Given the global epidemic of obesity and associated
‘metabolic syndrome’, this clinical context is essential to
know in guiding clinical management and in research/
interpretation of data. In our own series, for example,
we anticipate, that further stratification of cases within
the p53 wt subgroup (and possibly within MMR-D) by
BMI status may refine prognosis further. We are in the
process of examining the interaction of PTEN and BMI
within the ProMisE molecular subgroups across all of
our evaluable cohorts.
Rare histotypes and diversity within tumors
The role of molecular classification in rare histotypes of
endometrial carcinoma has not been determined. The
TCGA was restricted to cases of endometrioid and serous
histology, however, the TransPORTEC cohorts and our
own series included other histologies; 15% clear cell, and a
combination of 6% clear cell, carcinosarcoma, undifferenti-
ated, and mixed, in the cohorts respectively [69, 77, 79].
Fundamental features of the immunophenotype for dedif-
ferentiated, clear cell, and mixed carcinomas have been re-
ported [50, 54, 109–111]. Assessment of mixed tumors
show that despite morphologic differences/mimicry, the
majority of molecular aberrations are shared across the
tumor [112]. Thus the application of ProMisE or Leiden
classification systems to these cancers may be of value. In-
deed in the small number of non-serous, non-endometrioid
cases studied thus far, histotypes were distributed across
the molecular subgroups (not confined to p53 abn sub-
group). We anticipate there will be deeper characterization
of unique genomic categories; e.g., dedifferentiated carcin-
omas within p53 wt subgroup with mutations in the SWI/
SNF pathway.
Intratumoral heterogeneity in EC has been described
[113, 114], and might be predicted to weaken the utility
of ProMisE. However, in the cases examined, although
single nucleotide variations and copy number analysis
revealed some diversity between anatomic sites within
an individual (at time of diagnosis) the ProMisE molecular
subgroup categorization was concordant across all tumor
sites (6–14 anatomic sites examined per individual) [114].
We have reported on a case of discordant ProMisE
categorization between a diagnostic endometrial biopsy
and final hysterectomy specimen in an individual with a
dedifferentiated endometrial carcinoma [80]. This was
secondary to concurrent low grade and high grade areas
within the endometrium and myometrium where mismatch
repair profiles differed. In rare cases, in which diverse
tumor morphology is observed it may be that more
than one area needs to undergo molecular testing. Cer-
tainly, gross and microscopic assessment of endometrial
cancers by pathologists will need to continue just as rele-
vant post staging data on metastases may be weighed in
management. Successful integration of molecular classifi-
cation will require addressing all of these issues over time,
but in the interim, we anticipate a mix of current practice
(histomorphologic categorization) and molecular tools for
assessment of newly diagnosed ECs.
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Conclusions
We have harboured too long in a system of irreprodu-
cible categorization of endometrial carcinomas, incon-
sistent management within and across cancer centers,
and inappropriate research investigations that grouped
diverse tumors for study, making advances in research
and clinical management slow or impossible in this disease
site. It is essential that biologically relevant molecular
features are assessed and considered for categorization of
tumors, and in deciding surgical management and adjuvant
therapy. This does not require abandonment of clinicopath-
ologic parameters, many of which have been demonstrated
to maintain prognostic relevance even in the post-TCGA
era, but rather not to rely on them as the only or most
important feature to guide management.
We have shown that in the hands of two independent
research teams molecular classification of endometrial
carcinomas is feasible, and identifies four prognostically
distinct subgroups. Historical segregation of Type I
(mostly CN low, p53 wt cases) and Type II ECs (mostly
CN high, p53 abn subgroups) is inadequate and do not
account for the approximately 30% of cases that are
MMR-D or POLE EDM. All components of the molecular
classifier together can be achieved at a cost* comparable to
other commonly utilized clinical assays in cancer care.
At minimum, this system provides objective reproducible
categorization of EC’s. Familiarity with MMR and p53 IHC
testing and interpretation lends to rapid adoption in any
pathology department. The reproducibility of ProMisE
across Canadian cancer centers is currently being
evaluated.
Additional benefits of molecular classification include
early identification of women who may have an inherited
genetic syndrome (Lynch) who would benefit from add-
itional screening or interventions for other Lynch-
associated cancers or in whom specific therapies for their
Table 1 Potential changes in practice through molecular categorization
*Features that have been historically used in risk classification or are considered prognostic markers in other series
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endometrial carcinomas may be more effective. For young
women with EC considering delay of hysterectomy for
fertility reasons (e.g., progesterone therapy), molecular
classification of her diagnostic endometrial specimen
could help guide management as either MMR-D (de-
pending on germline results post hereditary cancer re-
ferral) or p53 abn categorization would discourage a
conservative approach. It is still unclear how knowing
the POLE mutation status within an individual’s EC will
impact her clinical management, as favorable outcomes
observed in these individuals may be either independent
or secondary to increased sensitivity to DNA damaging
agents (chemotherapy, radiation), and withholding treat-
ment cannot yet be advised. Plausibly, women with p53
abn tumors with higher association of metastatic disease
and aggressive clinical course would be recommended to
undergo more comprehensive surgical staging and closer
surveillance. Conversely, biologically indolent tumors
may be cured by simplified surgery alone and perhaps
spared toxic treatment and managed by community
gynecologists.
We are at an exciting juncture, but aware of the many
questions still remaining (Table 1). Through clinical trials,
we need to determine how molecular classification can be
best integrated in to current clinical care and how will it
impact outcomes. What, if any, additional parameters can
better inform management? Interrogation of genotypic and
phenotypic features may provide additional prognostic and
predictive information. These can now be explored within
the context of the four major molecular categories of tu-
mors, and even within molecular subgroups. How reliable
are IHC surrogates for mutational data in endometrial can-
cer? Characterization of p53 and other markers, as has been
achieved in ovarian cancer [115] is needed for this disease
site. Can molecular classification help interpret the natural
history and direct management of cases that have historic-
ally been a great challenge to manage e.g., grade 3 endome-
trioid carcinoma? What is the natural history of ECs with
two molecular features e.g. MMR-deficient and aberrant
p53? How often are these tumors encountered and how
should they be categorized? Is there a surrogate that
could replace sequencing for POLE? Are favorable out-
comes in POLE patients independent of treatment
(e.g., can these women be spared adjuvant therapy?)
Although there may be many questions to address we
anticipate that molecular classification will facilitate
rapid progress in research and clinical care as has been
achieved through a subtype specific approach in other
tumor sites.
In summary, whilst the combination of histomorphol-
ogy and clinical factors has proven to be insufficiently
reproducible, prognostic and predictive, two molecular
classifiers based on the TCGA study show great poten-
tial as pragmatic and effective tools to stratify patient
risk and subsequent care decisions. Given the high and
increasing incidence of endometrial cancer and the soci-
etal cost of over- and under-treatment there is urgent
need for prospective clinical studies to determine how
best to utilize these tools.
*For ProMisE; the materials, assay and interpret-
ation costs total < $300 USD
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